Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 1
1990 1
1991 2
1993 2
1994 2
1995 2
1996 4
1997 4
1998 6
1999 8
2000 9
2001 6
2002 7
2003 14
2004 9
2005 13
2006 15
2007 20
2008 21
2009 19
2010 21
2011 31
2012 28
2013 21
2014 34
2015 37
2016 48
2017 45
2018 41
2019 60
2020 76
2021 49
2022 44
2023 31
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

633 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL; ANDROMEDA Trial Investigators. Kastritis E, et al. N Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631. N Engl J Med. 2021. PMID: 34192431 Clinical Trial.
BACKGROUND: Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells. Daratumumab, a human CD38-targeting antibody, may improve outcomes for this disease. METHODS: We …
BACKGROUND: Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light ch …
How I treat AL amyloidosis.
Palladini G, Merlini G. Palladini G, et al. Blood. 2022 May 12;139(19):2918-2930. doi: 10.1182/blood.2020008737. Blood. 2022. PMID: 34517412 Free article.
However, hematologists are in the unique position to diagnose AL amyloidosis at a presymptomatic stage, checking biomarkers of amyloid organ involvement in patients with monoclonal gammopathies at higher risk to develop the disease. ...Therapy should be carefully ta …
However, hematologists are in the unique position to diagnose AL amyloidosis at a presymptomatic stage, checking biomarkers of …
Daratumumab in AL amyloidosis.
Wechalekar AD, Sanchorawala V. Wechalekar AD, et al. Blood. 2022 Dec 1;140(22):2317-2322. doi: 10.1182/blood.2021014613. Blood. 2022. PMID: 35507692 Free article. Review.
Early identification, correct fibril typing, challenges of the very advanced patient, and lack of therapies to remove amyloid deposits remain under study, but are, as yet, elusive. We review the progress of treatment in AL amyloidosis, the impact of daratumumab, and …
Early identification, correct fibril typing, challenges of the very advanced patient, and lack of therapies to remove amyloid deposits remai …
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Bumma N, Kaufman JL, Medvedova E, Kovacsovics T, Rosenzweig M, Sanchorawala V, Qin X, Vasey SY, Weiss BM, Vermeulen J, Merlini G, Comenzo RL. Palladini G, et al. Blood. 2020 Jul 2;136(1):71-80. doi: 10.1182/blood.2019004460. Blood. 2020. PMID: 32244252 Free PMC article. Clinical Trial.
Although no therapies are approved for light chain (AL) amyloidosis, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is considered standard of care. Based on outcomes of daratumumab in multiple myeloma (MM), the phase 3 ANDROMEDA study (NCT03201965) is eval …
Although no therapies are approved for light chain (AL) amyloidosis, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) …
Management of AL amyloidosis in 2020.
Palladini G, Milani P, Merlini G. Palladini G, et al. Blood. 2020 Dec 3;136(23):2620-2627. doi: 10.1182/blood.2020006913. Blood. 2020. PMID: 33270858 Free article. Review.
In amyloid light chain (AL) amyloidosis, a small B-cell clone, most commonly a plasma cell clone, produces monoclonal light chains that exert organ toxicity and deposit in tissue in the form of amyloid fibrils. ...The daratumumab+bortezomib combination is emerging a …
In amyloid light chain (AL) amyloidosis, a small B-cell clone, most commonly a plasma cell clone, produces monoclonal light ch …
Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review.
Gertz MA, Dispenzieri A. Gertz MA, et al. JAMA. 2020 Jul 7;324(1):79-89. doi: 10.1001/jama.2020.5493. JAMA. 2020. PMID: 32633805
The incidence of AL amyloidosis is approximately 12 cases per million persons per year and there is an estimated prevalence of 30 000 to 45 000 cases in the US and European Union. ...Therapeutic decision-making for AL amyloidosis involves choosing betw …
The incidence of AL amyloidosis is approximately 12 cases per million persons per year and there is an estimated prevalence of …
Systemic AL amyloidosis: current approach and future direction.
Bou Zerdan M, Nasr L, Khalid F, Allam S, Bouferraa Y, Batool S, Tayyeb M, Adroja S, Mammadii M, Anwer F, Raza S, Chaulagain CP. Bou Zerdan M, et al. Oncotarget. 2023 Apr 26;14:384-394. doi: 10.18632/oncotarget.28415. Oncotarget. 2023. PMID: 37185672 Free PMC article. Review.
Systemic Light chain (AL) amyloidosis is a monoclonal plasma cell proliferative disorder characterized by deposition of amyloidogenic monoclonal light chain fragments causing organ dysfunction. ...While it is widely accepted that the patients need to be treated unti …
Systemic Light chain (AL) amyloidosis is a monoclonal plasma cell proliferative disorder characterized by deposition of amyloi …
Comprehensive Review of AL amyloidosis: some practical recommendations.
Al Hamed R, Bazarbachi AH, Bazarbachi A, Malard F, Harousseau JL, Mohty M. Al Hamed R, et al. Blood Cancer J. 2021 May 18;11(5):97. doi: 10.1038/s41408-021-00486-4. Blood Cancer J. 2021. PMID: 34006856 Free PMC article. Review.
Amyloid light chain (AL) amyloidosis is among the more common and more severe of the amyloidoses usually involving the slow proliferation of a bone-marrow-residing plasma cell (PC) clone and the secretion of unstable immunoglobulin-free light chains (FLC) that infil …
Amyloid light chain (AL) amyloidosis is among the more common and more severe of the amyloidoses usually involving the slow pr …
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines.
Sanchorawala V, Boccadoro M, Gertz M, Hegenbart U, Kastritis E, Landau H, Mollee P, Wechalekar A, Palladini G. Sanchorawala V, et al. Amyloid. 2022 Mar;29(1):1-7. doi: 10.1080/13506129.2021.2002841. Epub 2021 Nov 16. Amyloid. 2022. PMID: 34783272
AL amyloidosis is a systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. High dose intravenous melphalan and autologous stem cell transplantation was developed for the treatment of AL amyloidosis in the early 1990s and was p …
AL amyloidosis is a systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. High dose intravenous mel …
Immunotherapy in AL Amyloidosis.
Zhang Y, Comenzo RL. Zhang Y, et al. Curr Treat Options Oncol. 2022 Jul;23(7):1059-1071. doi: 10.1007/s11864-021-00922-4. Epub 2022 May 30. Curr Treat Options Oncol. 2022. PMID: 35635625 Review.
Other immunotherapy agents including chimeric antigen receptor T cells, bispecific antibodies, and antibody-drug conjugates have altered the landscape in treatment of multiple myeloma, and are in the early phase of evaluation in patients with AL amyloidosis with res …
Other immunotherapy agents including chimeric antigen receptor T cells, bispecific antibodies, and antibody-drug conjugates have altered the …
633 results